ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO1160

Population-Level Trends in Kidney Function before and during the COVID-19 Pandemic: A Province-Wide Retrospective Study from Alberta, Canada

Session Information

  • COVID-19
    October 24, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Tungsanga, Somkanya, University of Alberta Faculty of Medicine & Dentistry, Edmonton, Alberta, Canada
  • Bello, Aminu K., University of Alberta Faculty of Medicine & Dentistry, Edmonton, Alberta, Canada
  • Oudit, Gavin, University of Alberta Faculty of Medicine & Dentistry, Edmonton, Alberta, Canada
  • Okpechi, Ikechi G., University of Alberta Faculty of Medicine & Dentistry, Edmonton, Alberta, Canada
Background

COVID19 infection is linked to the development of kidney-related adverse consequences via direct and indirect kidney injury. We explored changes in kidney function pre and during COVID-19 pandemic at population-level in Alberta, Canada.

Methods

This retrospective study using a province-wide administrative health data from Alberta, Canada, between 2018 and 2021. We included all adults residing in Alberta who had ≥1 annual visit to general practitioner and underwent outpatient serum creatinine tests. Data from each quarter of 2018-2019 was considered as pre-pandemic, while data from each quarter of 2020-2021 was considered during pandemic. Primary outcome was the proportion of individuals with eGFR decline, defined by sustained drop of ≥25% from baseline ≥3 months apart. Secondary outcome was the proportion of individuals with reduced eGFR who progressed to advanced stages of kidney dysfunction (eGFR <30 ml/min/m2).

Results

A total of 214,496 and 214,103 individuals were included in the study, pre-pandemic and during pandemic, respectively. The mean age was 58.3±17 years and 43% were male. At baseline, 16.5% and 17.3% of individuals had a reduced eGFR of <60 ml/min/m2 pre and during pandemic. The proportion of individuals with eGFR decline was higher during compared to pre pandemic era, particularly in the third and fourth quarter of 2020 (Q3: 3.2% vs 2.2%, Q4: 3.9% vs 2.9%) (Figure 1). Of those with reduced baseline eGFR, the proportion of individuals who progressed to advanced stages of kidney dysfunction was higher during the pandemic era.

Conclusion

This population-based, province-wide retrospective cohort showed a significant trend in the trajectory of kidney function decline with COVID-19 at the population level. These findings highlight the impact of the COVID-19 pandemic on kidney function, and a need for close monitoring of kidney function (particularly for the high-risk group) at the population level.

Proportion of individuals with eGFR decline in each quarter pre and during pandemic